Canaccord Genuity Maintains Buy on Neurocrine Biosciences, Raises Price Target to $210

Benzinga · 1d ago
Canaccord Genuity analyst Sumant Kulkarni maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $200 to $210.